Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The evolving paradigm of cancer trials

Nature Reviews Drug Discovery volume 17, pages 225–226 (2018)Cite this article

Subjects

The development of anticancer therapies is evolving with the advent of novel targeted drugs. In this Comment, I summarize some of the key changes and discuss the various choices for the optimal development of a new generation of cancer therapeutics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kummar, S. et al. Establishing proof of mechanism: assessing target modulation in early-phase clinical trials. Semin. Oncol. 43, 446–452 10.1053/j.seminoncol.2016.06.002 (2016).

    Article  CAS  PubMed  Google Scholar 

  2. Prowell, T. M., Theoret, M. R. & Pazdur, R. Seamless oncology-drug development. N. Engl. J. Med. 374, 2001–2003 (2016).

    Article  Google Scholar 

  3. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).

    Article  CAS  Google Scholar 

  4. Hyman, D. M. et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 373, 726–736 (2015).

    Article  CAS  Google Scholar 

  5. Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324–1334 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stanford University School of Medicine, 780 Welch Road, CJ250L, Palo Alto, 94305, California, USA

    Shivaani Kummar

Authors
  1. Shivaani Kummar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shivaani Kummar.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kummar, S. The evolving paradigm of cancer trials. Nat Rev Drug Discov 17, 225–226 (2018). https://doi.org/10.1038/nrd.2017.210

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2017.210

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research